James Cooper, MD

Professional Titles

• Associate Professor

Publications

• abstract at ATC meeting 2010 - pending
• "Optimizing immunosuppression" chapter in “Kidney Transplantation: A Guide to the Care of Transplant Recipients”
• Transplantation. 2009 Oct 15;88(7):891-6
• "Preemptive Retransplant for BK Virus Nephropathy Without Concurrent Transplant Nephrectomy" accepted in "Transplantation", in press
• "Novel Immunosuppressive Agents in Kidney Transplantation" accepted in "Clinical Nephrology", in press
• "Bortezomib Use in Chronic Antibody-Mediated Allograft Dysfunction: A Report of Three Cases" accepted in "Clinical Transplants" in press
• Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. “Inferior Kidney Allograft Outcomes in Patients with de novo Donor Specific Antibodies are Due to Acute Rejection Episodes.” Transplantation. 2011, in press
• Cooper JE, Wiseman AC, Chan L. “Bortezomib Use in Chronic Antibody-Mediated Allograft Dysfunction: Updates and Additional Cases.” Clin Transpl. 2011, in press
• Cooper JE, Huskey J, Chan L, Wiseman AC. “Preemptive Retransplant for BKV Nephropathy Without Concurrent Transplant Nephrectomy”. Transplantation. 2010 Aug 15;90(3):331-2
• Wiseman AC, Cooper JE, Chan L. “Clinical Aspects of Renal Transplantation” in Diseases of the Kidney. 2011. Chapter XX, in preparation
• Cooper JE, Christians U, Wiseman AC. “Everolimus in Kidney Transplantation.” Transplant Research and Risk Management. 2011, in press
• Cooper JE, Wiseman AC. “Optimizing Immunosuppression.” 2010. In Dianne McKay & Steven Steinberg, Kidney Transplantation, A guide to the Care of Kidney Transplant Recipients, Kidney Transplantation (pp 137-152). New York, NY: Springer
• ASN meeting 2010 oral abstract: Cooper JE, Gralla J, Goldberg R, Chan L, Wiseman AC. “Results of a Prospective Screening Protocol for De Novo Donor-Specific Antibody Development after Kidney Transplant”. ASN 2010 oral presentation
• ATC meeting 2011 oral abstract: James E. Cooper, MD1, Jane Gralla, PhD2, Linda Cagle3, Lawrence Chan, MD, PhD1 and Alexander C. Wiseman, MD1. “Inferior Graft Outcomes in Kidney Transplant Recipients with De Novo DSA are Due To High Antibody Titers and Prior Rejection Episodes”
• ATC meeting 2011 oral abstract: James E. Cooper, MD1, Linda Cagle2, Patrick Klem, PharmD3 and Alexander C. Wiseman, MD1. “High Dose IVIG for Treatment of Persistent Post-Kidney Transplant DSA”
• Clinical Significance of Post Kidney Transplant De Novo DSA in Otherwise Stable Grafts; Clinical Transplants 2011 (in press)
• Clinical Aspects of Renal Transplantation; book chapter in press
• Donor Specific Antibodies Detected by SAB Prior to Kidney Transplant Represent Minimal Risk Unless Associated with a Positive Cell-Based Flow Cytometry Cross-Match; ATC abstract accepted for 2012 annual meeting
• A case of cytomegalovirus-induced arthritis after lymphocyte-depleting therapy for kidney allograft rejection; Open Journal of Nephrology, 2012, 2, 1-4
• "Post-Transplant High Dose IVIG for De Novo Donor Specific Antibodies in Kidney Transplant Recipients with Graft Dysfunction" Transplantation, accepted with revisions
• “A Case of Cytomegalovirus-Induced Arthritis after Lymphocyte-Depleting Therapy for Kidney Allograft Rejection.” Open Journal of Nephrology, 2012, 2, 1-4
• “Evaluation and Management of Graft Dysfunction”, accepted, in preparation. Kidney Transplantation: A Practical Guide to Medical Management.
• “Prophylaxis and Treatment of Kidney Transplant Rejection”, accepted, in preparation. Comprehensive Clinical Nephrology, Fifth Edition.
• Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. “Post-Transplant High Dose IVIG for De Novo Donor Specific Antibodies in Kidney Transplant Recipients with Graft Dysfunction.” Transplantation, in press
• Cooper JE, Wiseman AC. Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens. 2013 Nov;22(6):698-703. PubMed PMID: 24076557
• Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013 Nov;24(11):1849-62. PubMed PMID: 24092930
• Cooper JE, Chan L, Wiseman AC. “The Patient With a Kidney Transplant”. 2013 in press. Manual of Nephrology, Eighth Edition. RW Schrier (Ed).
• Wiseman AC, Cooper JE. “Prophylaxis and Treatment of Kidney Transplant Rejection”, 2013 in press. Comprehensive Clinical Nephrology, Fifth Edition. Floege, Johnson, Feehally (Eds.).
• Wiseman AC, Cooper JE. “Evaluation and Management of Graft Dysfunction”, 2013 in press. Kidney Transplantation: A Practical Guide to Medical Management. Weir and Lerma (Eds.).
• Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation. 2014 Jun 27;97(12):1253-9. PubMed PMID: 24937199
• Shah P, Cooper JE, Lucia MS, Boils C, Larsen CP, Wiseman AC. APOL1 polymorphisms in a deceased donor and early presentation of collapsing glomerulopathy and focal segmental glomerulosclerosis in two recipients. Am J Transplant. 2016 Feb 5. [Epub ahead of print] PubMed PMID: 26849829
• Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015 Jun;26(6):1248-60. PubMed PMID: 25653099
• Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2017 Sep 19. [Epub ahead of print] PubMed PMID: 28925597
• Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant. 2017 Mar 22. [Epub ahead of print] PubMed PMID: 28332959
• Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients. Transplant Rev (Orlando). 2017 Jan;31(1):47-54. PubMed PMID: 28126347
• Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 Apr;18(4):907-915. PubMed PMID: 28925597
• Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM. Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2018 Jul 13;7(14). PubMed PMID: 30006493

Professional Memberships

• American Medical Assocation, Member
• Colorado Medical Society (CMS), Member

Practice Locations

UCHealth Transplant Center - Anschutz Medical Campus
1635 Aurora Ct
7th Floor
Aurora, CO 80045
720-848-0005

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Specialty Information

Specialties

• Nephrology, Board Certification

Conditions & Treatments

• Kidneys and Urinary System
• Surgery - Kidney Transplant Surgery
• Surgery
• Surgery - Living Kidney Donation